Mechanisms supporting Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder: A randomized, controlled clinical trial
Summary
The aim of this study is to determine if a single dose of psilocybin administered with motivational enhancement therapy (MET) can reduce heavy drinking in patients with an alcohol use disorder (AUD).
Eligible participants will be randomly allocated into either a high or low psilocybin dose group. All participant will be paired with a therapist and will receive up to 8 hours of preparation work prior to dosing. Following dosing participants will receive 5 weekly therapy sessions.
Clinical, behavioral and neuroimaging measures will be completed at various time points throughout the study.
Eligibility
Eligible gender: Male, Female, Transgender, Other
Eligible ages: 22 to 65
Inclusion criteria:
- Aged 22-65
- Regularly consume alcohol and wish to decrease consumption
- Limited lifetime hallucinogen use
Exclusion criteria:
- Diagnosis of; schizophrenia, bipolar disorders, or active suicidal ideation
- Currently pregnant, nursing, or trying to become pregnant
Participate
Fill out the following form if you want to participate in this research
Collection of personal information
Your personal information is collected under
the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If
you have any questions about the collection or use of this information, please visit our
Access to Information page.
Additional information
Contact information
If you are interested in applying for this study please complete the preliminary-screening form here: https://forms.office.com/r/KHvscxpnE2 OR contact pactlab@ucalgsry.ca if you have any questions.
Principal investigator:
Valerie Taylor
Clinical trial:
Yes
REB-ID:
REB23-0666